Muñoa L, González A B, Díaz de Rada P, Valentí A, Valentí J R
Department of Orthopaedic Surgery and Traumatology, School of Medicine, University of Navarre, Av. Pío XII 36, 31008, Pamplona, Spain,
Musculoskelet Surg. 2014 Jun;98(1):21-5. doi: 10.1007/s12306-013-0287-7. Epub 2013 Jul 14.
The aim of this study is to compare effectiveness and safety profile of rivaroxaban with bemiparin in 3-week extended prophylaxis after knee arthroscopy.
Four hundred and sixty-seven patients were included in this review divided in two groups. One followed prophylaxis with rivaroxaban and the other one with bemiparin. All patients were interviewed and explored at 1 and 3 months postoperatively, looking for symptomatic signs of deep-vein thrombosis (DVT). In case of suspicion, diagnostic tests were performed. Collected data were age, sex, gender, diagnosis, time with ischemia, body mass index, concomitant diseases, concomitant therapy, DVT signs, treatment satisfaction, minor and major complications, treatment adherence and tolerability.
No thromboembolic events were observed in any of the groups. In one case treated with rivaroxaban, the drug had to be withdrawn due to epistaxis.
Our study showed that extended prophylaxis with 10 mg of rivaroxaban once daily for 3 weeks resulted as effective as bemiparin in knee arthroscopy thromboprophylaxis.
本研究旨在比较利伐沙班与倍他肝素在膝关节镜检查后3周延长预防治疗中的有效性和安全性。
本综述纳入467例患者，分为两组。一组采用利伐沙班进行预防，另一组采用倍他肝素。所有患者在术后1个月和3个月接受访谈和检查，寻找深静脉血栓形成（DVT）的症状体征。如有怀疑，则进行诊断检查。收集的数据包括年龄、性别、诊断、缺血时间、体重指数、伴随疾病、伴随治疗、DVT体征、治疗满意度、 minor和major并发症、治疗依从性和耐受性。
两组均未观察到血栓栓塞事件。在1例接受利伐沙班治疗的患者中，因鼻出血不得不停药。
我们的研究表明，膝关节镜检查血栓预防中，每天一次10 mg利伐沙班进行3周的延长预防治疗与倍他肝素效果相同。
